ACR Appropriateness Criteria® resectable stomach cancer Journal Article
| Authors: | Daroui, P.; Jabbour, S. K.; Herman, J. M.; Abdel-Wahab, M.; Azad, N.; Blackstock, A. W.; Das, P.; Goodman, K. A.; Hong, T. S.; Jones, W. E.; Kaur, H.; Konski, A. A.; Koong, A. C.; Kumar, R.; Pawlik, T. M.; Small, W.; Thomas, C. R.; Suh, W. W. |
| Article Title: | ACR Appropriateness Criteria® resectable stomach cancer |
| Abstract: | For resectable gastric cancer, perioperative chemotherapy or adjuvant chemoradiation with chemotherapy are standards of care. The decision making for adjuvant therapeutic management can depend on the stage of the cancer, lymph node positivity, and extent of surgical resection. After gastric cancer resection, postoperative chemotherapy combined with chemoradiation should be incorporated in cases of D0 lymph node dissection, positive regional lymph nodes, poor clinical response to induction chemotherapy, or positive margins. In the setting of a D2 lymph node dissection, especially those with negative regional lymph nodes, adjuvant chemotherapy alone could be considered. The American College of Radiology (ACR) Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review includes an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. © 2015, UBM Medica Healthcare Publications. All rights reserved. |
| Keywords: | cancer chemotherapy; overall survival; cancer recurrence; intensity modulated radiation therapy; bevacizumab; cisplatin; fluorouracil; capecitabine; disease free survival; postoperative care; radiation dose; outcome assessment; cancer diagnosis; lymph node dissection; progression free survival; computer assisted tomography; lomustine; folinic acid; gastrectomy; stomach cancer; esophageal adenocarcinoma; stomach adenocarcinoma; disease specific survival; endoscopic echography; randomized controlled trial (topic); phase 2 clinical trial (topic); meta analysis (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); endoscopic mucosal resection; controlled clinical trial (topic); adjuvant chemoradiotherapy; human; article |
| Journal Title: | Oncology (Norwalk) |
| Volume: | 29 |
| Issue: | 8 |
| ISSN: | 0890-9091 |
| Publisher: | C M P Medica LLC * The Oncology Group |
| Date Published: | 2015-08-15 |
| Start Page: | 595 |
| End Page: | 602 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 26281845 |
| DOI/URL: | |
| Notes: | Export Date: 2 September 2015 -- Source: Scopus |
